Patients And Families Aspect Ratio 1200 384

Patients & Caregivers

A new approach to transform treatment and potentially cure AML

Vor Bio is working to transform treatment and ultimately cure Acute Myeloid Leukemia (AML) and other blood cancers.

Combining proven technologies in new ways, our unique approach aims to protect your healthy blood cells while enabling the use of powerful targeted therapies against cancer cells that may remain following your Hematopoietic Cell Transplant (HCT).

For some types of AML, HCT is the only potentially curative option. However, in many cases, AML can relapse even after transplant. A major challenge following transplant is that many of the current therapies that are intended to kill the cancer cells can also target and destroy healthy blood cells. Our approach is based on an elegant idea: make HCTs resistant to cancer-directed therapies so that healthy blood cells are protected, but cancer cells can be directly targeted for destruction. Healthy donor hematopoietic stem cells (HSCs) are first edited to remove a marker on the outside of the cells so that they can no longer be recognized by targeted therapies.

Once you recover from your HCT with the modified healthy donor cells, you may now be able to receive a targeted therapy to kill any remaining cancer cells and to decrease the chance that the cancer can come back—only possible because your healthy cells are now “invisible” to the targeted therapy.

What is AML?

Acute Myeloid Leukemia (AML) is a form of blood cancer that progresses quickly and prevents healthy blood cells from getting produced.

About Our Investigational Program

Our approach is based upon an elegant idea: make your healthy cells resistant to targeted therapies, allowing them to pass over the good cells and focus their effects on the bad cells—the cancer cells. By protecting healthy cells, we aim to create new treatment opportunities for targeted therapies and attack the cancer when it is weakest following HCT.

Dive In Deeper

African American Doctor Talking To Patient In Office

Our Clinical Trials

You may be eligible to participate.

Two Sisters

Patient / Donor Journey

Our approach requires a healthy matched donor.

Patient Advocacy Hero Aspect Ratio 600 400

Patient Advocacy

We partner with and depend on the support of many cancer organizations.